Sage Therapeutics (SAGE) to Release Quarterly Earnings on Tuesday

Sage Therapeutics (NASDAQ:SAGE) is anticipated to issue its quarterly earnings data after the market closes on Tuesday, February 11th. Analysts expect the company to announce earnings of ($1.54) per share and revenue of $14.37 million for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Sage Therapeutics Stock Performance

SAGE stock opened at $7.25 on Monday. The firm has a market cap of $443.48 million, a PE ratio of -1.30 and a beta of 0.94. Sage Therapeutics has a one year low of $4.62 and a one year high of $27.39. The firm’s 50 day moving average price is $6.25 and its 200-day moving average price is $6.98.

Analyst Ratings Changes

SAGE has been the subject of a number of research analyst reports. Royal Bank of Canada upgraded Sage Therapeutics from an “underperform” rating to a “sector perform” rating and set a $4.00 price target for the company in a report on Thursday, November 21st. Piper Sandler dropped their price target on shares of Sage Therapeutics from $26.00 to $9.00 and set an “overweight” rating for the company in a research report on Thursday, January 2nd. TD Cowen reduced their price target on shares of Sage Therapeutics from $10.00 to $9.00 and set a “hold” rating on the stock in a research note on Thursday, November 21st. Needham & Company LLC reaffirmed a “hold” rating on shares of Sage Therapeutics in a research report on Wednesday, November 20th. Finally, Oppenheimer cut their target price on Sage Therapeutics from $9.00 to $8.00 and set a “market perform” rating on the stock in a research report on Wednesday, October 30th. Three analysts have rated the stock with a sell rating, sixteen have given a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, Sage Therapeutics currently has an average rating of “Hold” and a consensus price target of $10.53.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.